BUZZ-Insulet falls as analysts see pricing headwinds in Q1

Shares of medical device maker Insulet PODD.O fall 3% to $279.52

"Pacing of how rebates will be recognized in the pharmacy channel brings headwind to Q1 U.S. growth, but nets out evenly through remaining quarters," says brokerage Oppenheimer

Rebates are paid by drug manufacturers to pharmacy benefit managers (PBM), which act as middlemen between drug companies and consumers, in exchange for favorable placement of their drugs on insurer coverage lists

"With 100% of the U.S. business in the pharmacy and a better relationship with the PBMs, there's much less lumpiness, and Insulet won't be experiencing the normal price bump from rebating in Q1," says J.P.Morgan

Brokerage BTIG analyst Marie Thibault says 2025 revenue forecasts may be viewed as "somewhat underwhelming"

Co expects annual revenue to grow between 16% and 20%

Its total revenue jumped 17.2% to $597.5 million for Q4, beating analysts' estimates of $582.8 million, according to data compiled by LSEG

Sales of Omnipod insulin pumps also beat estimates

PODD has risen ~47% in the last 12 months